This study focuses on treating patients with moderate-to-severe asthma, a condition where airways become inflamed and narrow, making breathing difficult. The research evaluates a new medication called amlitelimab, which is given as a subcutaneous injection (an injection under the skin). The study aims to determine how well different doses of amlitelimab work compared to placebo in people whose asthma is not well controlled with their current treatments.

The medication being tested, amlitelimab (also known as SAR445229), is a new type of medicine that targets specific components of the immune system that may be involved in asthma. During the study, participants will receive either amlitelimab or placebo injections over a period of 48 weeks. The maximum single dose that may be given is 500 milligrams, with a total possible amount of 2,750 milligrams over the entire treatment period.

Throughout the study, doctors will monitor how well the treatment works by tracking various aspects of participants’ asthma, including how often they experience severe asthma attacks, their breathing capacity, and how well they can control their symptoms. They will also keep track of any side effects that may occur during the treatment period.